<DOC>
	<DOCNO>NCT00859885</DOCNO>
	<brief_summary>The prevalence patent foramen ovale ( PFO ) 25 % general population approximately 40 % patient ischemic stroke unknown cause ( cryptogenic stroke ) . Given large number asymptomatic patient , primary prevention currently recommend . On contrary , secondary prevention important . Prospective study show antithrombotic treatment ( ATT ) aspirin warfarin appear negate risk recurrent stroke associate PFO . Patients spontaneous large right-to-left shunt ( RLS ) , coincide atrial septal aneurysm ( ASA ) multiple ischemic event prior PFO diagnosis may still increase risk stroke recurrence despite ATT . Percutaneous device closure ( PDC ) challenge alternative ATT . Several study report 0 % 3.4 % annual recurrence rate stroke TIA patient treat PDC . To date , data randomize control trial ( RCT ) compare risk stroke recurrence PDC ATT . The result ongoing RCTs await near future , mainly due low enrolment event rate . Alternative data-gathering strategy multicenter registry need overcome low recruitment rate . The aim present study compare risk recurrent stroke TIA patient PFO otherwise unexplained stroke undergo PDC receive ATT .</brief_summary>
	<brief_title>International PFO Consortium</brief_title>
	<detailed_description>Background The prevalence patent foramen ovale ( PFO ) 25 % general population approximately 40 % patient ischemic stroke unknown cause ( cryptogenic stroke ) . Given large number asymptomatic patient , primary prevention currently recommend . On contrary , secondary prevention important . Prospective study show antithrombotic treatment ( ATT ) aspirin warfarin appear negate risk recurrent stroke associate PFO . Patients spontaneous large right-to-left shunt ( RLS ) , coincide atrial septal aneurysm ( ASA ) multiple ischemic event prior PFO diagnosis may still increase risk stroke recurrence despite ATT . Percutaneous device closure ( PDC ) challenge alternative ATT . Several study report 0 % 3.4 % annual recurrence rate stroke TIA patient treat PDC . To date , data randomize control trial ( RCT ) compare risk stroke recurrence PDC ATT . The result ongoing RCTs await near future , mainly due low enrolment event rate . Even RCTs complete successfully , statistical difference may remain undetected planned sample size . Alternative data-gathering strategy multicenter registry need overcome low recruitment rate . Objective 1 ) To compare risk recurrent stroke TIA patient age â‰¤ 55 year PFO otherwise unexplained stroke undergo PDC receive ATT ; 2 ) To assess etiological role PFO stroke/TIA patient age &gt; 55 year ; 3 ) To assess risk recurrent stroke/TIA `` high-risk '' PFO patient ( i.e . spontaneous ( rest ) large RLS , coincide ASA , multiple previous cerebrovascular event ) . Methods Multicenter prospective non-randomized study schedule 3-years follow-up patient PFO ischemic stroke TIA . Participating center : Swiss University Hospitals Basel , Bern , Geneva , Lausanne Zurich , Cantonal Hospital Aarau , Triemli Hospital , Alfried-Krupp Krankenhaus Essen , University Hospital Essen , Klinikum Worms gGmbH , Tufts Medical Center , Baystate Medical Center , East Medical Center Tyler , University Hospital Leuven .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<mesh_term>Foramen Ovale , Patent</mesh_term>
	<criteria>Age &gt; 18 year Diagnosis PFO establish transesophageal echocardiography ( TEE ) Ischemic stroke transient ischemic attack within previous 6 month Exclusion Criteria Nonvascular origin neurological symptom brain imaging ( CT scan MRI ) Comorbid condition would interfere study Pregnancy History intracranial bleeding , confirm arteriovenous malformation , aneurysm uncontrolled coagulopathy Contraindications TEE , echocardiographic iodine contrast medium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>patent foramen ovale</keyword>
	<keyword>ischemic stroke</keyword>
	<keyword>transient ischemic attack</keyword>
	<keyword>secondary prevention</keyword>
	<keyword>medical treatment</keyword>
	<keyword>percutaneous device closure</keyword>
</DOC>